Abstract
Chimeric antigen receptor (CAR) T-cell therapy is a promising immunotherapy against cancer. The idea is to fortify a person’s immune system to fight its own battle by boosting T cells with the ability to ferret out tumor-associated antigens. But engineering CAR-T cells is an arduous process, and they are usually customized to recognize only one antigen. In a new paper, one research group reports broadening the versatility of engineered CAR-T cells by bringing into the fold functionalized antibodies that act as universal adapters between the CAR-T cell and various tumor antigens ( Nat. Commun. 2023, DOI: 10.1038/s41467-023-37863-5 ). “An antibody is . . . easier to chemically modify than an entire cell,” says Alexander Deiters, a University of Pittsburgh chemist and a coauthor of the study. The researchers engineered CAR-T cells with receptors that carry a SNAPtag label, a modified O 6 -methylguanine-DNA methyltransferase. This SNAPtag can covalently bind with
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
